Vanesa Quiroga
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 20, 2025
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.
Journal: Clinical and translational medicine
Published: May 20, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 28, 2025
Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response.
Journal: Translational oncology
Published: April 09, 2025
Molecular Landscape, Genomic Shift, and Prediction in the Neoadjuvant Setting of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: February 05, 2025
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Journal: International journal of molecular sciences
Published: September 17, 2024
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.
Journal: Therapeutic advances in medical oncology
Published: July 13, 2024
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study.
Journal: ESMO open
Published: April 18, 2024
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: October 17, 2023
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Journal: Frontiers in oncology
Published: May 22, 2023
Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer.
Journal: Cancers
Published: April 13, 2023
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Journal: The Lancet. Oncology
Published: January 19, 2023
Last Updated: 09/26/2026